New compound shows promise as a more effective treatment for schistosomiasis

A newly developed compound is showing promise in animal studies as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms.

TRYP THERAPEUTICS RECEIVES CONFIRMATION FROM FDA TO PROCEED WITH PHASE 2A CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL – Biotech Investments

, 07/13/2023 / 06:00, EST/EDT – EQS Newswire – Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange,

July 14, 2023

Gilead reports 8.45% dip in net income for Q2 2023

The company declared dividends of $944m for the latest quarter and also repurchased $150m of its common stock. Credit: Michael Vi / Shutterstock.com. Gilead Sciences

August 4, 2023

Danaher/Abcam deal set to close next month; Cereno’s loan; March Biosciences to advance its CAR-T into PhII

Danaher’s proposed acquisition of Abcam is expected to close Dec. 6: The companies announced the closing date on Friday. Danaher is paying $24 a share

November 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.